-
Neck pain is common among the general population. Half of those patients who report this symptom have persistent complaints at 1 year. At particular risk for persistent neck pain are those ages 45-59 years, those with chronic low back pain, and patients who ride their bicycles regularly.
-
Survival benefits in the first year after acute MI, in patients 65 years or older, seem to differ according to specific ACE I prescribed.
-
-
A new, and as of yet unpublished study, has raised increased concern about the relationship between rofecoxib (Vioxx), Mercks blockbuster COX-2 inhibitor, and cardiovascular events.
-
-
Viagra: Maximum Capacity at High-Altitudes?; FDA Actions.
-
The High Cost of MRSA; Treatment of Latent TB: A High Priority; The APRICOT HCV/HIV Co-infection Study.
-
Nitazoxanide (Alinia) is a broad spectrum antiparasitic agent, previously approved for use as an oral suspension for the treatment of cryptosporidiosis and giardiasis in children. It has now received FDA approval as a 500 tablet for the treatment of giardiasis in adolescents and adults.
-
Caspofungin and flucytosine were the active antifungals against C. glabrata, while fluconazole was least active. Isolates with high level resistance to fluconazole demonstrated reduced susceptibility to voriconazole.
-
Host factors are the major determinants of the outcomes of C. meningosepticum infections. Lin and colleagues describe 9 adults (40-82 years of age) and 2 children (0.5 and 1.5 years of age) seen at 2 hospitals in Taiwan from 2001 to 2002 with bacteremia due to Chrysobacterium meningosepticum. Six of the infections were community acquired.
